Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome

References

• Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39(3):403–414. doi: 10.1007/s10072-017-3188-y
   PubMed Web of Science ®Google Scholar
• Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(s5):3–9. doi: 10.1111/j.1528-1167.2011.03177.x
   PubMedGoogle Scholar
• Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox–Gastaut syndrome: treatment algorithms and practical considerations [Review]. Front Neurol. 2017 Sep 8;8. English. DOI:10.3389/fneur.2017.00505
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93. doi: 10.1016/S1474-4422(08)70292-8
   PubMed Web of Science ®Google Scholar
• Samanta D. Management of Lennox-Gastaut syndrome beyond childhood: a comprehensive review. Epilepsy Behav. 2021;114:107612. doi: 10.1016/j.yebeh.2020.107612
   PubMed Web of Science ®Google Scholar
• Autry AR, Trevathan E, Van Naarden Braun K, et al. Increased risk of death among children with lennox-gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441–447. PubMed PMID: 20023065. doi: 10.1177/0883073809348355
   PubMed Web of Science ®Google Scholar
• Berg AT, Levy SR, Testa FM. Evolution and course of early life developmental encephalopathic epilepsies: focus on Lennox-Gastaut syndrome. Epilepsia. 2018;59(11):2096–2105. doi: 10.1111/epi.14569
   PubMed Web of Science ®Google Scholar
• Brigo F, Jones K, Eltze C, et al. Anti‐seizure medications for Lennox‐Gastaut syndrome. Cochrane Database Syst Rev. 2021;4(9). PubMed PMID: CD003277. doi: 10.1002/14651858.CD003277.pub4
   PubMedGoogle Scholar
• Besag FM, Vasey MJ, Chin RF. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome. Expert Opin Pharmacother. 2023;24(11):1249–1268. (just-accepted). doi: 10.1080/14656566.2023.2215924
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE Guideline [NG217] 2022 [cited 2023 Nov 28]. Available from: https://www.nice.org.uk/guidance/ng217
   Google Scholar
• Medicines and Healthcare products Regulatory Authority (MHRA). Valproate: reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in th coming months 2022 [updated 2022 Dec 12; cited 2023 Oct 30]. Available from: https://www.gov.uk/drug-safety-update/valproate-reminder-of-current-pregnancy-prevention-programme-requirements-information-on-new-safety-measures-to-be-introduced-in-the-coming-months
   Google Scholar
• British national formulary (BNF) online. Treatment summaries: epilepsy [cited 2023 Nov 28]. Available from: https://bnf.nice.org.uk/treatment-summaries/epilepsy/
   Google Scholar
• Polster T. Individualized treatment approaches: fenfluramine, a novel antiepileptic medication for the treatment of seizures in dravet syndrome. Epilepsy Behav. 2019;91:99–102. doi: 10.1016/j.yebeh.2018.08.021
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies. CNS Drugs. 2021;35(1):61–83. doi: 10.1007/s40263-020-00784-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Orphan designation for the treatment of Dravet syndrome 2013 [updated 2023 Apr 25; cited 2023 Oct 20]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1219
   Google Scholar
• European Medicines Agency (EMA). Orphan designation for the treatment of Lennox-Gastaut syndrome 2017. [updated 2023 Apr 25; cited 2023 Oct 20]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1836
   Google Scholar
• Lagae L, Schoonjans A-S, Gammaitoni AR, et al. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome. Epilepsia. 2018;59(10):1881–1888. doi: 10.1111/epi.14540
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). FDA approves new therapy for Dravet syndrome 2020 [cited 2023 Oct 20]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-dravet-syndrome
   Google Scholar
• US Food and Drug Administration (FDA). New drug therapy approvals 2022 [cited 2023 Oct 20]. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022
   Google Scholar
• Li R, Serdula MK, Williamson DF, et al. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy. Int J Obes. 1999 Sep 01;23(9):926–928. doi: 10.1038/sj.ijo.0801020
   PubMed Web of Science ®Google Scholar
• Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in SCN1A mutant zebrafish. Front Pharmacol. 2017;8:191. PubMed PMID: 28428755; PubMed Central; PMCID: PMCPMC5382218. eng. doi: 10.3389/fphar.2017.00191
   PubMed Web of Science ®Google Scholar
• Martin P, Gammaitoni A, Farfel G, et al. 663. An examination of the mechanism of action of fenfluramine in dravet syndrome: a look beyond serotonin. Biological Psychiatry. 2017;81(10):S268–S269. doi: 10.1016/j.biopsych.2017.02.1072
   Web of Science ®Google Scholar
• Martin P, de Witte PAM, Maurice T, et al. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020 Apr;105:106989. PubMed PMID: 32169824; eng. doi: 10.1016/j.yebeh.2020.106989
   PubMed Web of Science ®Google Scholar
• Rodríguez-Muñoz M, Sánchez-Blázquez P, Garzón J. Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget. 2018 May 4;9(34):23373–23389. doi: 10.18632/oncotarget.25169 PubMed PMID: 29805740; PubMed Central; PMCID: PMCPMC5955088. eng.
   PubMedGoogle Scholar
• Patsalos PN. Fenfluramine. Antiseizure medication interactions: a clinical guide. Cham: Springer International Publishing; 2022. p. 81–84.
   Google Scholar
• Balagura G, Cacciatore M, Grasso EA, et al. Fenfluramine for the treatment of Dravet syndrome and Lennox–Gastaut syndrome. CNS Drugs. 2020;34(10):1001–1007. doi: 10.1007/s40263-020-00755-z
   PubMed Web of Science ®Google Scholar
• UCB Pharma. FINTEPLA (fenfluramine) oral solution prescribing information 2023 [cited 2023 Oct 19]. Available from: https://www.ucb.com/sites/default/files/2023-09/Fintepla_Current_COL_15_Sept_2023.pdf
   Google Scholar
• Samanta D. Fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. Children. 2022;9(8):1159.
   PubMedGoogle Scholar
• Dini G, Di Cara G, Ferrara P, et al. Reintroducing fenfluramine as a treatment for seizures: current knowledge, recommendations and gaps in understanding [review]. Neuropsychiatr Dis Treat. 2023;19:2013–2025. PubMed PMID: 2886403318; 2026101352; Eng. doi: 10.2147/NDT.S417676
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019 Jan;57(1):11–19. PubMed PMID: 30336805; PubMed Central PMCID: PMCPMC6298132. eng. doi: 10.5414/cp203276
   PubMed Web of Science ®Google Scholar
• Schoonjans A-S, Roosens L, Dewals W, et al. Therapeutic drug monitoring of fenfluramine in clinical practice: pharmacokinetic variability and impact of concomitant antiseizure medications. Epilepsia. 2022;63(3):686–696. doi: 10.1111/epi.17162
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Farfel GM, et al., editors. A phase 1, single-dose, open-label pharmacokinetic study to investigate the drug-drug interaction potential of ZX008 (Fenfluramine HCl oral solution) and Cannabidiol. 73rd American Epilepsy Society Annual Meeting; Baltimore, Maryland, US. 2019 Dec.
   Google Scholar
• Electronic Medicines Compendium (emc). Fintepla 2.2 mg/mL oral solution. Summary Of Product Characteristics (SmPC) 2023 [updated 09 Oct 2023; cited 01 Dec 2023]. Available from: https://www.medicines.org.uk/emc/product/11998/smpc#gref
   Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–2254. doi: 10.1016/S0140-6736(19)32500-0
   PubMed Web of Science ®Google Scholar
• Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–564. doi: 10.1001/jamaneurol.2022.0829
   PubMed Web of Science ®Google Scholar
• Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2023;64(1):139–151. doi: 10.1111/epi.17431
   PubMed Web of Science ®Google Scholar
• Devi N, Madaan P, Ameen R, et al. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: a network meta-analysis. Seizure. 2022;99:164–175. doi: 10.1016/j.seizure.2022.04.004
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang J, Wang C. Efficacy and safety of antiseizure medication for Lennox–gastaut syndrome: a systematic review and network meta‐analysis. Dev Med Child Neurol. 2022;64(3):305–313. doi: 10.1111/dmcn.15072
   PubMed Web of Science ®Google Scholar
• Ng Y-T, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox–Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav. 2012;25(4):687–694. doi: 10.1016/j.yebeh.2012.09.039
   PubMed Web of Science ®Google Scholar
• Ng Y-T, Conry J, Mitchell WG, et al. Clobazam is equally safe and efficacious for seizures associated with Lennox–Gastaut syndrome across different age groups: post hoc analyses of short- and long-term clinical trial results. Epilepsy Behav. 2015;46:221–226. doi: 10.1016/j.yebeh.2015.01.037
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, et al. Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial. Epilepsy Res. 2016;121:1–7. doi: 10.1016/j.eplepsyres.2016.01.002
   PubMed Web of Science ®Google Scholar
• Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122(3):202–208. doi: 10.1111/j.1600-0404.2010.01334.x
   PubMed Web of Science ®Google Scholar
• Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(9):2228–2239. doi: 10.1111/epi.17000
   PubMed Web of Science ®Google Scholar
• Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Roger J, Bureau M Dravet C, editors Epileptic syndromes in infancy, childhood and adolescence. 4th ed. London: John Libby Eurotext; 2005. p. 125–148.
   Google Scholar
• Bishop KI, Isquith PK, Gioia GA, et al. Fenfluramine treatment improves everyday executive functioning in patients with Lennox-Gastaut syndrome: analysis from a phase 3 clinical trial. Neuropediatrics. 2021;52(S 01):2.09. En. doi: 10.1055/s-0041-1739606
   Google Scholar
• Bishop K, Isquith P, Giola G, et al. Fenfluramine improves everyday executive functioning in patients with Lennox-Gastaut syndrome: analysis of phase 3 data [conference abstract]. Neurology. 2022 May;98(18 SUPPL). PubMed PMID: 2687892945; 638416824; Eng. 10.1212/WNL.98.18_supplement.3017
   Google Scholar
• Bishop K, Isquith P, Knupp K, et al. Fenfluramine treatment is associated with improvement in everyday executive function in adults with Lennox-Gastaut syndrome: post hoc analysis of dose effects from a phase 3 trial rationale [conference abstract]. Neurology. 2023 Apr;100(17). PubMed PMID: 2831528036; 641671689; Eng. 10.1212/WNL.0000000000202479
   Web of Science ®Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–308. doi: 10.1001/jamaneurol.2019.4113
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med. 1997;337(9):581–588. PubMed PMID: 9271479. doi: 10.1056/nejm199708283370901
   PubMed Web of Science ®Google Scholar
• Wong J, Reddy S, Klein AL. Anorectic drugs and valvular heart disease: a biological and clinical perspective. Cleve Clin J Med. 1998;65(1):35–41. doi: 10.3949/ccjm.65.1.35
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997;46(47):1061–1066.
   PubMedGoogle Scholar
• Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24(2):309–314. doi: 10.1111/ene.13195
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans A-S, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):e129–e134. doi: 10.1111/epi.13407
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131–1139. doi: 10.1111/j.1528-1167.2012.03495.x
   PubMed Web of Science ®Google Scholar
• Sullivan J, Lagae L, Cross J, et al. Fenfluramine (FINTEPLA) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (study 3). Proceedings of the American Epilepsy Society; Virtual. 2020.
   Google Scholar
• Agarwal A, Farfel GM, Gammaitoni AR, et al. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: findings from serial echocardiographic assessments. Eur J Paediatr Neurol. 2022;39:35–39. doi: 10.1016/j.ejpn.2022.05.006
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Sullivan J, Ceulemans B, et al. Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy Behav. 2021;122:108212. doi: 10.1016/j.yebeh.2021.108212
   PubMed Web of Science ®Google Scholar
• Eschbach K, Scarbro S, Juarez-Colunga E, et al. Growth and endocrine function in children with Dravet syndrome. Seizure. 2017;52:117–122. doi: 10.1016/j.seizure.2017.09.021
   PubMed Web of Science ®Google Scholar
• Armeno M, Verini A, Del Pino M, et al. A prospective study on changes in nutritional status and growth following two years of ketogenic diet (KD) therapy in children with refractory epilepsy. Nutrients. 2019;11(7):1596.
   PubMed Web of Science ®Google Scholar
• Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American epilepsy society. Epilepsy Curr. 2017;17(3):180–187. PubMed PMID: 28684957. doi: 10.5698/1535-7511.17.3.180
   PubMed Web of Science ®Google Scholar
• Young C, Shankar R, Henley W, et al. SUDEP and seizure safety communication: assessing if people hear and act. Epilepsy Behav. 2018;86:200–203. doi: 10.1016/j.yebeh.2018.06.040
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia. 2011;52(6):1150–1159. doi: 10.1111/j.1528-1167.2010.02952.x
   PubMed Web of Science ®Google Scholar
• Sveinsson O, Andersson T, Mattsson P, et al. Clinical risk factors in SUDEP. A nationwide population-based case-control study. Neurology. 2020;94(4):e419–e429. doi: 10.1212/wnl.0000000000008741
   PubMed Web of Science ®Google Scholar
• Cross JH, Galer BS, Gil-Nagel A, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154–159. doi: 10.1016/j.seizure.2021.10.024
   PubMed Web of Science ®Google Scholar
• Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43–47. doi: 10.1016/j.eplepsyres.2016.10.006
   PubMed Web of Science ®Google Scholar
• Tupal S, Faingold CL. Fenfluramine, a serotonin-releasing drug, prevents seizure-induced respiratory arrest and is anticonvulsant in the DBA/1 mouse model of SUDEP. Epilepsia. 2019;60(3):485–494. doi: 10.1111/epi.14658
   PubMed Web of Science ®Google Scholar
• British National Formulary For ChIldren (BNFC) online. Fenfluramine - medicinal forms [cited 2023 Nov 28]. Available from: https://bnfc.nice.org.uk/drugs/fenfluramine/medicinal-forms/
   Google Scholar